valproic acid and aspirin

Aspirin (salicylate) displaces valproic acid from plasma protein binding sites, increasing the free fraction of valproic acid. Salicylate also inhibits the beta-oxidation pathway of valproic acid metabolism, reducing its clearance. These combined effects raise free valproic acid concentrations, which are responsible for pharmacological and toxic effects.

The free valproic acid level may rise even when the total concentration remains within the reference range. This can lead to dose-related valproate toxicity, including nausea, vomiting, sedation, ataxia, confusion, and in severe cases coma and respiratory depression. Aspirin also has an antiplatelet effect, so concurrent use may increase the risk of bleeding, particularly in patients already at risk.

Avoid co-prescription if possible. If combined therapy is necessary, monitor the patient closely for signs of valproate toxicity and consider monitoring free valproic acid concentration (if available) in addition to total levels. Reduce the valproic acid dose as clinically indicated. Educate the patient about symptoms of toxicity and bleeding. Alternative analgesics or antiplatelet agents should be considered.

The interaction is well established. Studies demonstrate that aspirin increases the free fraction of valproic acid and reduces its clearance, leading to higher free valproate concentrations. However, the extent of clinical toxicity varies and requires individual assessment.